1. Boehringer Ingelheim, G. Pyrrolidino ketones, United States Patent Office, 3314970 A, (1967). https://www.google.com/patents/US3478050. (Accessed September 21, 2018).
2. Jacob P., Shulgin A. Inventors, Neurobiological Technologies, Inc., assignee. Preparation of novel N-substituted-2-amino-3,4-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents. US Patent WO9639133 A1 (1996). https://www.google.com/patents/WO1996039133A1?cl=en. (Accessed September 21, 2018).
3. EMCDDA. European Drug Report 2018: Trends and Developments, Publications Office of the European Union, Luxembourg (2018). http://www.emcdda.europa.eu/publications/edr/trends-developments/2018. (Accessed September 21, 2018).
4. EMCDDA. Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1-penteanone (alpha-PVP) (2015). http://www.emcdda.europa.eu/system/files/publications/1814/TDAS15001ENN.pdfhttp://www.emcdda.europa. (Accessed September 21, 2018).
5. Instituto Nacional de Toxicología y Ciencias Forenses. Ministerio de Justicia. Gobierno de España. Memoria INTCF 2016. http://www.mjusticia.gob.es/cs/Satellite/Portal/1292428739049?blobheader=application%2Fpdf&blobheadername1=ContentDisposition&blobheadername2=Grupo&blobheadervalue1=attachment%3B+filename%3DMemoria_INTCF_2016.PDF&blobheadervalue2=INTCF.